STERIS(STE) - 2026 Q3 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Total as-reported revenue grew 9% in the third quarter, with constant currency organic revenue increasing by 8% driven by volume and a 200 basis points price increase [4] - Gross margin declined by 70 basis points to 43.9%, primarily due to increased tariffs and inflation [4] - EBIT margin decreased by 40 basis points to 22.9% of revenue, mainly driven by the decline in gross margin [4] - Adjusted net income from continuing operations was $249.4 million, with earnings per diluted share increasing by 9% to $2.53 [5] - Free cash flow for the first nine months of fiscal 2026 was $736.6 million, showing year-over-year improvement [6] Business Line Data and Key Metrics Changes - Healthcare segment saw constant currency organic revenue growth of 8%, with service growing 11% and consumables growing 8% [7] - Healthcare capital equipment revenue increased by 7%, with backlog remaining over $400 million [7] - AST segment's constant currency organic revenue grew 8%, with services up 9% and capital equipment revenue up 103% [8] - Life sciences segment experienced a 5% increase in constant currency organic revenue, driven by 11% growth in consumables [8] Market Data and Key Metrics Changes - Orders in the healthcare segment were down 1% year-to-date against tough comparisons from the previous year [7] - The backlog in life sciences is showing strong growth, attributed to recovery in the pharma sector [16] Company Strategy and Development Direction - The company is maintaining its outlook for fiscal 2026, expecting 8%-9% as-reported revenue growth and constant currency organic revenue growth of 7%-8% [9] - The company is focused on mitigating tariff impacts through various strategies, including supplier negotiations and cost reductions [24] - There is a commitment to a more integrated commercial approach in the EMEA region, with structural changes being made to enhance market presence [34] Management's Comments on Operating Environment and Future Outlook - Management expressed caution regarding the fourth quarter, anticipating a slowdown compared to the previous year [12] - The macro environment appears positive, with no significant downside expected for fiscal 2027 [50] - The company is optimistic about its ability to absorb tariff-related costs moving forward [24] Other Important Information - Capital expenditures for the first nine months of fiscal 2026 totaled $278.8 million, with depreciation and amortization at $363.1 million [6] - The company ended the quarter with $1.9 billion in total debt, with a gross debt to EBITDA ratio of approximately 1.2 times [6] Q&A Session Summary Question: Insights on fourth quarter constant currency growth - Management noted a potential slowdown in the second half, maintaining a cautious outlook for the fourth quarter [12][14] Question: Capital equipment backlog activity - Management indicated stability in healthcare backlog and strong growth in life sciences backlog due to recovery in pharma spending [16] Question: Update on tariff mitigation efforts - Management discussed various mitigation strategies, including shifting product movement and supplier negotiations [24] Question: Impact of regulatory proposals on supply chain - Management stated that the ASC shift is generally positive, creating new capacity demands [31] Question: Future acquisition outlook - Management confirmed ongoing interest in smaller acquisitions but emphasized a disciplined approach to larger transformative deals [44] Question: Cash flow guidance and fluctuations - Management expressed confidence in cash flow guidance but noted potential timing issues in the fourth quarter [48] Question: AST Services growth and market conditions - Management acknowledged a weak start to the quarter but noted improvement by December [57]